Aclaris Therapeutics Initiates Phase 1 Clinical Trial for ATI-50001, an Investigational JAK Inhibitor, for the Treatment of Alopecia Totalis and Alopecia Universalis
December 07, 2016 08:00 ET
|
Aclaris Therapeutics, Inc.
MALVERN, Pa., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), today announced that its Investigational New Drug (IND) Application for ATI-50001, an orally administered...
Aclaris Therapeutics to Attend Upcoming Investor Conferences
November 22, 2016 08:00 ET
|
Aclaris Therapeutics, Inc.
MALVERN, Pa., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced that management will host investor...
Aclaris Announces Pricing of Public Offering of Common Stock
November 17, 2016 19:02 ET
|
Aclaris Therapeutics, Inc.
MALVERN, Pa., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced the pricing of its underwritten public...
Aclaris Therapeutics annonce des résultats de phase 3 positifs de premier ordre pour le A-101 dans le traitement de la kératose séborrhéique, une affection cutanée fréquente, insuffisamment traitée...
November 16, 2016 22:10 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics annonce des résultats de phase 3 positifs de premier ordre pour le A-101 dans le traitement de la kératose séborrhéique, une affection cutanée fréquente, insuffisamment...
Aclaris Therapeutics vermeldet positive Top-Line-Ergebnisse der Phase 3 für A-101 zur Behandlung von seborrhoischer Keratose, einer häufig auftretenden, nicht ausreichend behandelten Hauterkrankung
November 16, 2016 22:10 ET
|
Aclaris Therapeutics, Inc.
Schlüsseldaten zeigen, dass die topische Behandlung statistisch signifikante Ergebnisse erbrachte, die alle primären und sekundären Endpunkte erfüllenAclaris reicht Antrag auf Arzneimittelzulassung...
Aclaris Announces Proposed Public Offering of Common Stock
November 16, 2016 16:05 ET
|
Aclaris Therapeutics, Inc.
MALVERN, Pa., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced that it intends to offer and sell,...
Aclaris Therapeutics Announces Positive Top-Line Phase 3 Results for A-101 In Treating Seborrheic Keratosis, a Common Undertreated Skin Condition
November 15, 2016 16:08 ET
|
Aclaris Therapeutics, Inc.
Pivotal Data Show Topical Treatment Delivered Statistically Significant Results, Meeting All Primary and Secondary EndpointsAclaris to Submit New Drug Application to FDA in 1Q17 Company to Host...
Aclaris Therapeutics Reports Third Quarter 2016 Financial Results
November 03, 2016 07:00 ET
|
Aclaris Therapeutics, Inc.
MALVERN, Pa., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage specialty pharmaceutical company, today announced financial results for the third quarter...
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-50001 to Treat Alopecia Universalis and Alopecia Totalis
October 31, 2016 08:00 ET
|
Aclaris Therapeutics, Inc.
MALVERN, Pa., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and...
Aclaris Therapeutics Honored as One of the Best Places to Work in Pennsylvania
October 28, 2016 08:00 ET
|
Aclaris Therapeutics, Inc.
MALVERN, Pa., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc., (NASDAQ:ACRS), a dermatologist-led, specialty pharmaceutical company focused on the development of medical and aesthetic...